menu
    • menu
    [{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nymox Pharmaceutical

    Menu

    Nymox Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Required to Resubmit Application to DKMA

                            Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostate enlargement (BPH).

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Reports New NYMOZARFEX Marketing Application is Accepted for Review

                            Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostatic hyperplasia.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 26, 2023

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH

                            Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostatic hyperplasia.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 25, 2023

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results

                            Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for low grade early prostate cancer.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 25, 2023

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

                            Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostate enlargement (BPH).

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NYMOX Announces New Marketing Submission for NYMOZARFEX for BPH

                            Details : Nymozarfex (fexapotide triflutate) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

                            Details : NX-1207 (fexapotide triflutate), is a protein injectable for benign prostatic hyperplasia and for low grade localized prostate cancer, a new molecular entity which safely targets prostate glandular cells that have proliferated in BPH.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2022

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Nymox Pharmaceutical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Jour...

                            Details : Safety data showed no serious adverse events related to FT during the study.

                            Product Name : Nymozarfex

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 24, 2020

                            Lead Product(s) : Fexapotide triflutate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth